Costar Technologies, Inc. Announces Date of 2017 Annual Meeting of Stockholders

Costar Technologies, Inc. Announces Date of 2017 Annual Meeting of Stockholders

PR Newswire

COPPELL, Texas, Aug. 18, 2017 /PRNewswire/ – Costar Technologies, Inc. (the “Company”) (OTC Markets Group: CSTI), announced today that the Company’s 2017 Annual Meeting of Stockholders will be held on October 4, 2017 at 3:00 p.m. local time at its corporate headquarters located at 101 Wrangler Drive, Suite 201, Coppell, TX 75019. The Company also announced that it has set the close of business on August 15, 2017 as the record date for determining the stockholders entitled to receive notice of and vote at the annual meeting.

The Company anticipates mailing its proxy statement to stockholders on or around August 28, 2017, which will include a description of the matters to be considered at the annual meeting. Stockholders may also obtain a copy of the 2017 proxy statement when it is available as well as other information concerning the Company at www.costartechnologies.com.   


About Costar Technologies, Inc.

Costar Technologies, Inc. develops, designs and distributes a range of security solution products including surveillance cameras, lenses, digital video recorders and high-speed domes. The Company also develops, designs and distributes industrial vision products to observe repetitive production and assembly lines, thereby increasing efficiency by detecting faults in the production process. Headquartered in Coppell, Texas, the Company’s shares currently trade on the OTC Markets Group under the ticker symbol “CSTI”. Costar was ranked 41 in a&s magazine’s Security 50 for 2016. Security 50 is an annual ranking of the world’s largest security manufacturers in the areas of video surveillance, access control and intruder alarms and is based on financial performance.


Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. You can identify forward-looking statements by words such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other comparable terminology. These forward-looking statements are based on management’s current expectations but they involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of the risks and uncertainties.

You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable laws.

 

View original content:http://www.prnewswire.com/news-releases/costar-technologies-inc-announces-date-of-2017-annual-meeting-of-stockholders-300506762.html

SOURCE Costar Technologies, Inc.

Global Pharmaceutical Robots Market 2014-2017 & 2025 – Market is Anticipated to Reach USD 430.0 Million

Logo

Global Pharmaceutical Robots Market 2014-2017 & 2025 – Market is Anticipated to Reach USD 430.0 Million

PR Newswire

DUBLIN, August 18, 2017 /PRNewswire/ —

The “Pharmaceutical Robots Market Analysis By Product (Traditional, Collaborative), By Application (Picking & Packaging, Inspection of Pharmaceutical Drugs, Laboratory Applications), By End Use, And Segment Forecasts, 2014 – 2025” report has been added to Research and Markets’ offering.

Research and Markets Logo

The global pharmaceutical robots market is anticipated to reach USD 430.0 million by 2025

This growth can be attributed to the flourishing pharmaceutical industry.

The pharmaceutical industry is flourishing due to huge R&D investments by global players. With increasing drug discovery and clinical trials, there is growing demand for robotics. To minimize workload and maintain higher levels of accuracy, automation has become a significant part of pharmaceutical manufacturing. It increases efficiency, prevents performance of repetitive activities, and avoids human error & contamination.

Technological advancement is an important factor driving growth. The use of robots & automated machines in the field of pharmaceuticals is still in its nascent stage and expected to grow in the near future. The automation industry has incorporated a few new techniques such as collaborative robots and laboratory automation.

Pharmaceutical robotic machines also minimize manufacturing costs by reducing labor. These machines are 3 to 4 times faster than humans and have the capacity to work for 24 hours. Reduction in production cost is expected to raise return on investment in the long run, thus driving demand for these products in the future.

Key Topics Covered:

1 Research Methodology

2. Executive Summary

3. Pharmaceutical Robots Market Variables, Trends & Scope

4. Pharmaceutical Robots Market: Product Estimates & Trend Analysis

5. Pharmaceutical Robots Market: Application Estimates & Trend Analysis

6. Pharmaceutical Robots Market: End-use Estimates & Trend Analysis

7. Pharmaceutical Robots Market: Regional Estimates & Trend Analysis, by Product, Application, End-use

8. Competitive Landscape

  • Kawasaki Heavy Industries Ltd.
  • FANUC America Corporation
  • ABB Ltd.
  • Yaskawa Electric Corporation
  • Denso Wave Inc.
  • Seiko Epson Corporation
  • Marchesini Group S.p.A
  • Universal Robots A/S

For more information about this report visit https://www.researchandmarkets.com/research/73lnbz/pharmaceutical

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

View original content:http://www.prnewswire.com/news-releases/global-pharmaceutical-robots-market-2014-2017–2025—market-is-anticipated-to-reach-usd-4300-million-300506506.html

SOURCE Research and Markets

Biopharmaceutical CMO & CRO Market to Value $37.8 Billion by 2025: Regional Estimates & Trend Analysis, by Service, Source, & Product

Logo

Biopharmaceutical CMO & CRO Market to Value $37.8 Billion by 2025: Regional Estimates & Trend Analysis, by Service, Source, & Product

PR Newswire

DUBLIN, August 18, 2017 /PRNewswire/ —

The “Biopharmaceutical CMO & CRO Market, 2014 – 2025” report has been added to Research and Markets’ offering.

Research and Markets Logo

The global biopharmaceutical CMO & CRO (contract manufacturing & research) market is expected to reach USD 37.8 billion by 2025, according to this new report.

Healthy outlook of biopharmaceuticals and consequent growth in biopharmaceutical pipelines has resulted into lack of adequate capacity and budget constraints. These factors have convinced many traditional drug developers to take advantage of cost-saving benefits associated with contract services. Traditional biopharmaceutical players are observed to choose outsourcing biopharmaceutical manufacturing rather than making an investment of expensive capital in production equipment and hiring skilled labor.

Significant improvement in the services offered by this CMOs/CROs in context to maturity of complex technology is spurring the adoption of these services. In addition, wide acceptance of single-use technology within CMOs/CROs has significantly transformed the CMOs/CROs landscape by enhancing their capabilities and enabling them to develop products at low operating costs.

Outsourcing services are observed to play critical role in overcoming trade barriers for firms. It enables them to make footprints in foreign market where government regulates to secure local employment through domestic production. Furthermore, as a result of growing demand for these services, smaller companies have also begun to expand their non-GMP facilities.

Companies Mentioned

  • Boehringer Ingelheim GmbH
  • LONZA
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologie GmbH
  • JRS PHARMA
  • CELONIC AG
  • BIOMEVA GmbH
  • ProBioGen
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • TOYOBO CO., LTD.
  • Samsung BioLogics
  • Patheon
  • DPx
  • CMC Biologics
  • Binex Co., Ltd.
  • WuXi Biologics
  • AbbVie, Inc.

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Market Variables, Trends & Scope

4. Biopharmaceuticals CMO & CRO Market: Source Estimates & Trend Analysis

5. Biopharmaceuticals CMO & CRO Market: Service Type Estimates & Trend Analysis

6. Biopharmaceuticals CMO & CRO Market: Product Estimates & Trend Analysis

7. Biopharmaceuticals CMO & CRO Market: Regional Estimates & Trend Analysis, by Service, Source, & Product

8. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/m6q67t/biopharmaceutical

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/biopharmaceutical-cmo–cro-market-to-value-378-billion-by-2025–regional-estimates–trend-analysis-by-service-source–product-300506468.html

SOURCE Research and Markets